Suven Life Sciences, a biopharmaceutical company, surges by almost 3 per cent as it has secured product patents in Brazil and Eurasia for the treatment of neurodegenerative diseases. The product patent acquired by the company in Brazil will be valid through 2023, while the product patent acquired in Eurasia will be valid through 2024.